Healthbae Immuno Gains | Curcumin & Piperine Capsules BCM-95 | Patented & Scientifically Formulated

1. MOOD SWING AND STRESS

In a study, the mood-modulating activity of IMMUNO GAINS (BCM-95®) and its combination with SSRIs was studied in various tests. The effect of curcumin (100 mg/kg) was similar to that of SSRIs (p > 0.05) but its addition to SSRIs did not improve their activity (p >0.05). It was concluded that its mood- modulating activity could be due to an increase in serotonin, norepinephrine and dopamine levels in the brain. Curcumin can be a useful mood-modulator especially in cases that respond to drugs having mixed effects on serotonin and catecholamines levels in the brain.

Several studies have demonstrated the healthy mood support effects of curcumin and saffron. In a randomized, double-blind, placebo-controlled study, 123 individuals were allocated to one of four treatment conditions.  It was concluded that differing doses of curcumin and combined curcumin/saffron were effective in supporting healthy mood function.

3. LIVER HEALTH

A study evaluated hepatoprotective activity in combination of Phyllanthus niruri and Curcuma longa extracts IMMUNO GAINS (BCM-95®) against CCl4 induced hepatotoxicity. The histological section of the liver in animals treated with CCl4 showed a centrilobular area of necrosis with derangement in hepatic architecture. PN+CL administration prevented these deleterious changes, the histological section of the liver in rats treated with PN+CL showed normal hepatic parenchyma. The combination of Phyllanthus niruri + Curcuma longa extracts showed significant hepatoprotection against CCl4 induced liver damage.

Liver Support

Poster presented at the IPSCON 44th Annual Conference of Indian Pharmacological Society, 2011 The study evaluated hepatoprotective activity in combination of Phyllanthus niruri and Curcuma longa extracts IMMUNO GAINS (BCM-95®) against CCl4 induced hepatotoxicity. Wistar rats weighing 150-200 g were divided into 3 groups (n=6). Group I- Control, Group II-CCl4 (0.5 mg/kg IP), Group III- CCl4 (0.5 mg/kg IP) with PN+CL (400 mg/kg) were administered for 7 days. On the 8th day, Serum Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP) and Total bilirubin (TB) were estimated. Histopathological assessment was done using liver tissue. Analysis was done using one way ANOVA.

4. JOINT HEALTH

In a pilot phytotherapy clinical study conducted in 2012, we evaluated the safety and effectiveness of curcumin alone, and in combination with an NSAID. The primary and secondary endpoints were a reduction in (DAS) 28 score and ACR score. These are assessments used by clinicians that measure various joint-related parameters. Subjects in all three treatment groups showed statistically significant changes in their DAS scores. Interestingly, the curcumin group showed the highest percentage of improvement in overall DAS and ACR scores (ACR 20, 50 and 70) and these were significantly better than the subjects in the NSAID group. More importantly, the curcumin treatment was found to be safe and did not relate to any adverse events.

5. URINARY HEALTH

Some previous in vitro and in vivo studies have proposed a radio protective role for curcumin. The purpose of this investigation was to assess the radio protective effects of curcumin supplementation in subjects undergoing external beam radiotherapy (EBRT). Quality of life was assessed by the quality of life questionnaire (QLQ-PR25). Analysis of covariance was used to compare radiotherapy related symptoms between groups following the intervention, adjusted for baseline symptoms. The change in urinary symptoms across the 20-week period differed significantly between groups (p=0.011) and subjects in the curcumin group experienced much milder urinary symptoms compared with the placebo group. No group differences were observed in any other domain of the QLQ-PR25. Curcumin can confer radio protective effect in through reducing the severity of radiotherapy related urinary symptoms

6. BREAST HEALTH

IMMUNO GAINS (BCM-95®) is a major ingredient in BreastDefend (BD). A study was conducted to evaluate the effect of the dietary supplement BD on the proliferation and invasive behavior in MDA-MB-231 breast cells treated with BD (0-40 μg/mL) by MTT assay and trypan blue staining, respectively. The effect of BD on invasiveness was assessed by cell adhesion, migration, and invasion assays. BD treatment suppressed the invasive behavior of MDA-MB-231 cells by the inhibition of cellular adhesion, migration, and invasion.

This inhibition of invasiveness was mediated by the suppression of secretion of urokinase plasminogen activator (uPA), and by the down regulation of expression of CXCR4 in breast cancer cells treated with BD. Conclusion: BD inhibits proliferation and invasive behavior of MDA-MB-231 cells in vitro. BD may have a therapeutic potential for breast health support.

7. INFLAMMATERY RESPONSE

Among obesity-associated disorders, low-grade inflammation has been described. A study confirmed that hesperidin and naringin or highly bioavailable curcumin extract have beneficial effects, targeted in the liver and could improve the obesity-related inflammatory state. In another study, anti-inflammatory activity of bio-enhanced turmeric formulation IMMUNO GAINS (BCM-95®) was compared with commercial curcumin formulation (curcuminoids 95%) in Carrageenan-induced acute inflammatory model. In this study, all treatment groups demonstrated significant (p < 0.05) anti-inflammatory activity. The authors concluded that IMMUNO GAINS (BCM- 95®) treated groups showed significant healthy inflammatory response support compared to curcuminoid 95% treated groups.